DCC 2618

Drug Profile

DCC 2618

Alternative Names: DCC-2618

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Gastrointestinal stromal tumours; Glioblastoma; Systemic mastocytosis

Most Recent Events

  • 05 Jun 2017 Updated efficacy, safety and pharmacokinetics data from a phase I trial in Gastrointestinal stromal tumours presented at the 53rd Annual meeting of the American Society of Clinical Oncology Annual Meeting (ASCO-2017)
  • 05 Jun 2017 Deciphera Pharmaceuticals plans two pivotal phase III trials for Gastrointestinal stromal tumours (Second-line therapy or greater)
  • 03 Apr 2017 Updated results from a phase I trial in Gastrointestinal stromal tumours released by Deciphera Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top